News | Heart Valve Technology | July 22, 2015

Direct Flow Medical Announces FDA Approval to Broaden SALUS U.S. Trial

Expansion brings high-risk surgical patients, randomization against Medtronic CoreValve into trial

Direct Flow Medical, Transcatheter Aortic Valve System, SALUS Trial, FDA

July 22, 2015 Direct Flow Medical Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) in April to broaden its SALUS Trial. The expansion includes the addition of high-risk patients and randomization against a commercial device, the Medtronic CoreValve. 

The SALUS Trial is a prospective, randomized, multi-center, core lab adjudicated U.S. clinical trial, evaluating the Direct Flow Medical Transcatheter Aortic Valve System. The primary endpoint of the trial is a composite of all-cause mortality and disabling stroke at 12 months. Principal investigators for the SALUS Trial are Murat Tuzcu M.D., vice chairman of the Department of Cardiology, Cleveland Clinic; and Patrick McCarthy, M.D., director of the Bluhm Cardiovascular Institute and chief of cardiac surgery, Northwestern Memorial Hospital.

The expansion of the SALUS Trial includes the following changes:

  • Treatment of high surgical risk patients and continued treatment of extreme risk patients;
  • 2:1 randomization to Medtronic CoreValve;
  • 912 subject pivotal cohort;
  • Up to 45 sites in the U.S.; and
  • Registries for non-femoral access points and type 2 and 3 bicuspid valves.

 

The repositionable and retrievable Direct Flow Medical system is designed to treat patients with severe aortic stenosis who are at high or extreme surgical risk by replacing the native aortic valve, while minimizing the degree and frequency of aortic regurgitation (AR). AR has been shown to be a strong predictor of long-term mortality. The system is designed to address this clinical concern by sealing the annulus and enabling complete assessment of hemodynamic performance with repositioning of the valve after full deployment. The system is designed to avoid rapid pacing of the heart during deployment and post-dilatation following placement, minimizing the risk of hemodynamic instability for patients.

"We have been working closely with the FDA since the early development of the Direct Flow Medical technology and it has been a collaborative effort with the FDA which has led to an expansion of the SALUS trial. The technology has shown outstanding performance in clinical trials and commercial settings, significantly reducing the risk of aortic regurgitation with excellent survival. We look forward to expanding the clinical use to additional centers in the U.S. and continuing to obtain the same strong outcomes in the pivotal trial," said Tuzcu.

An earlier feasibility phase of the SALUS Trial conducted in 2013 evaluated the system in 30 patients. Thirty-day outcomes demonstrated a survival rate of 97 percen, with 100 percent of patients experiencing mild or less aortic regurgitation. Results also showed low procedural complications, no incidence of stroke and a three percent rate of permanent pacing. The mean aortic gradient decreased from 44.5 mmHg to 12.7 mmHg at 30 days. The previous protocol of the SALUS Trial enrolled more than 100 extreme risk patients in a non-randomized fashion and will continue to be followed independently.

The Direct Flow Medical system received the CE Mark in January 2013 and is currently available commercially in Europe.

For more information: www.directflowmedical.com

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
Overlay Init